# A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Source: https://onco.cc/trials/nct06764875/  
OnCo record `nct06764875` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, Capecitabine and Cisplatin in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.

## Summary

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer is a phase 3 interventional study registered as NCT06764875 by AstraZeneca, with 840 participants planned, started 2025-03-01 and due to reach its primary completion in 2029-04-27. Interventions recorded: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil and Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: ARTEMIDE-Gastric01
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06764875
- Phase: 3
- Setting: A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
- Sponsor: AstraZeneca
- Enrolled: 840

## Sources

- ClinicalTrials.gov NCT06764875: https://clinicaltrials.gov/study/NCT06764875

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06764875.json